Kura Oncology Announces Results From Registration-Directed Study Of Tipifarnib In Patients With HRAS Mutant HNSCC
Portfolio Pulse from Benzinga Newsdesk
Kura Oncology has announced results from a study of Tipifarnib in patients with HRAS mutant HNSCC, showing meaningful antitumor activity. The data supports the rapid advancement of KO-2806 into combinations with targeted therapies in large solid tumor indications. The results will be presented at the 2023 ESMO Congress.
October 17, 2023 | 8:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kura Oncology's positive study results for Tipifarnib could potentially boost the company's stock in the short term as it indicates progress in their product pipeline.
Positive clinical trial results often lead to increased investor confidence as they indicate progress in a company's product pipeline. This could potentially lead to an increase in Kura Oncology's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100